Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450536 | 0.83 | CDK1 (0.45) | CDK1AKT1 | |
| SCHEMBL448404 | 0.81 | PPARG (0.41) | AKT1 | |
| SCHEMBL447288 | 0.80 | ADORA2A (0.49) | — | |
| SCHEMBL465001 | 0.79 | ADORA2A (0.45) | CDK1CDK2 | |
| SCHEMBL28320166 | 0.78 | CDK1 (0.50) | CDK1CCNB1CCNE1CDK2CDK5 | |
| SCHEMBL448173 | 0.77 | ADORA2A (0.40) | — | |
| SCHEMBL449667 | 0.75 | ADORA2A (0.38) | — | |
| SCHEMBL7743666 | 0.72 | ADORA3 (0.69) | — | |
| SCHEMBL28083712 | 0.70 | CDK1 (0.76) | CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL28319035 | 0.70 | CDK1 (0.55) | CDK1CCNB1CCNE1CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778239-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN'S SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2007-05-02 | — | — | EP | claimed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | claimed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | claimed |
| WO-2006011130-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN’S SYNDROME | CAN-FITE BIOPHARMA LTD. (IL) | 2006-02-02 | — | — | WO | claimed |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| EP-3906034-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | Can-Fite Biopharma Ltd. (IL) | 2021-11-10 | — | — | EP | disclosed |
| CN-113543790-A | Use of A for achieving a fat-reducing effect3Adenosine receptor ligands | 坎-菲特生物药物有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-108367016-B | A3 adenosine receptor ligands for the treatment of ectopic fat accumulation | 坎-菲特生物药物有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | CAN-FITE BIOPHARMA LTD (IL) | 2021-03-11 | — | — | US | disclosed |
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN-FITE BIOPHARMA LTD. (IL) | 2020-12-10 | — | — | US | disclosed |
| EP-3380104-B1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN FITE BIOPHARMA LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| US-10780106-B2 | Method for treating NASH accompanied by fibrosis using Cl-IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2020-09-22 | — | — | US | disclosed |
| EP-1959939-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | Can-Fite Biopharma Ltd. (IL) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007086044-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS | CAN-FITE BIOPHARMA LTD. (IL) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007063538-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | CAN-FITE BIOPHARMA LTD. (IL) | 2007-06-07 | — | — | WO | disclosed |
| US-20070099865-A1 | Treatment of dry eye conditions | CAN-FITE BIOPHARMA LTD. (IL) | 2007-05-03 | — | — | US | disclosed |
| EP-1778239-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN'S SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2007-05-02 | — | — | EP | disclosed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | disclosed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | disclosed |
| WO-2006011130-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN’S SYNDROME | CAN-FITE BIOPHARMA LTD. (IL) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099865-A1 | Treatment of dry eye conditions | ADORA3, ADORA2A, ADORA2B | CDK1 4171/4885CCNB1 3570/4885CCNE1 4044/4885 |
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | GPR119, ADORA2A, FABP4 | CDK1 4761/4885CCNB1 3432/4885CCNE1 4133/4885 |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA3, ADORA2A, ADORA1 | CDK1 1237/4885CCNB1 1495/4885CCNE1 1308/4885 |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | ADORA3, ADORA2A, IL1RN | CDK1 4077/4885CCNB1 4739/4885CCNE1 4683/4885 |
| US-10780106-B2 | Method for treating NASH accompanied by fibrosis using Cl-IB-MECA | GPR119, FABP1, INSR | CDK1 4661/4885CCNB1 1834/4885CCNE1 3664/4885 |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | ADORA2A, ADORA3, ADORA1 | CDK1 1240/4885CCNB1 789/4885CCNE1 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.